市場調查報告書
商品編碼
927806
肝腎症候群治療的全球市場:成長,趨勢,預測(2020年~2025年)Hepatorenal Syndrome Treatment Market - Growth, Trends, and Forecasts (2022 - 2027) |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
肝腎症候群治療市場在預測期間內預計將以全體年複合成長率約6.2%成長。肝腎綜合徵是一種在嚴重肝損害的人中發現的一種進行性腎功能衰竭,最常由肝硬化引起。當腎臟衰竭時,毒素開始在體內蓄積並最終導致肝衰竭。促進市場增長的主要因素是肝損害和肝硬化的患病率增加。根據疾病控制與預防中心的數據,僅在美國,2018年就有450萬成年人被診斷出患有慢性肝病。此外,更多的快速通道和孤兒藥名稱將推動市場增長。但是,藥品的嚴格監管要求和副作用限制了市場的增長。
本報告提供全球肝腎症候群治療市場調查,提供市場概要,各不同治療·各地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。
The hepatorenal syndrome treatment market is projected to record a CAGR of nearly 6.2% over the forecast period. Hepatorenal syndrome is a type of progressive kidney failure seen in people with severe liver damage, most often caused by cirrhosis. As the kidneys stop functioning, toxins begin to build up in the body. Eventually, this leads to liver failure. The major factor attributing to the growth of the market is the increase in the prevalence of liver damage and cirrhosis. According to the Centers for Disease Control and Prevention, 4.5 million adults are diagnosed with chronic liver disease in the year 2018, in the United States alone. Furthermore, increasing fast-track and orphan drug designations boosts the market growth. However, side effects with the drugs and stringent regulations are restraining the market growth.
The therapeutics segment is expected to grow at a greater phase as the patients prefer taking drugs than undergoing surgeries. Furthermore, increasing fast track and orphan designations to the drugs is further boosting the segment. Several drugs have received orphan drug designation, thereby accelerating their approval process, and this can act as a factor pushing the growth of the therapeutics segment. For instance, in November 2018, BioVie Inc. announced that the FDA granted Orphan Drug designation to its Terlipressin drug for the treatment of the hepatorenal syndrome. The designation for orphan drugs allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials, along with seven years of market exclusivity upon regulatory approval. This is likely to drive the hepatorenal syndrome treatment market during the forecast period.
North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors, such as the presence of key players, established healthcare infrastructure, increased prevalence of severe liver damage and cirrhosis are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. In this region, the United States has the maximum share due to supportive healthcare policies, high number of patients, and a developed healthcare market. According to the US Department of Health and Human Services,1 in 400 adults in the United States has cirrhosis for the year 2018. As per the statistics the increasing patient pool and increasing disposable revenue in this country boost the market growth of the region.
The hepatorenal syndrome treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, New Medicon Pharma Lab, Becton, Dickinson and Company, Edwards Lifesciences Corporation, Aetna Inc.,Baxter, Fuji Systems Corp, Johnson & Johnson Co, G Surgiwear Ltd.